-
A randomized double-blind placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
This is a research study that aims to determine if adding darolutamide to the standard treatment, ADT (referred to as androgen deprivation therapy which is ...
Phase
Interventional
